For Biocellvia, 2019 is full of promise

Biocellvia ended up successfully a business trip in San Diego
Biocellvia ended up successfully a business trip in san diego
décembre 18, 2018
EASL International Liver Congress
Biocellvia presented a poster at the International Liver Congress
juillet 24, 2019
Show all

For Biocellvia, 2019 is full of promise

2019 a year full of promise for Biocellvia

Good news for Biocellvia. 2019 is beginning as well as possible. We are very proud to announce a new reference publicly. We have a collaboration with Ridgeline Therapeutics, an american biotech based in Texas. 2019 will be a key year for the development of Biocellvia with important events that will impact the company as key milestones.

Scientific acknowledgement in 2018, 2019 full of promise

2019 is a year full of promise for Biocellvia. Our technology is more and more acknowledged with major scientific articles that will be published this year. Biocellvia’s scientific team takes part to more and more scientific collaborations with research institutions implicated in NASH and pulmonary diseases.

In 2018, Pr. Yvon Julé, Biocellvia’s Chief Scientific Officer (CSO) co-signed scientific publications with Dr. Bernhard Ryffel, research director at CNRS, Dr. Stephanie Solier from Gustave Roussy (biggest european research institution dedicated to oncology). Pr. Isabelle Leclercq from Université of Louvain, key opinion leader on NASH, joined our scientific advisory board as Dr. Ryffel and Dr. Solier too.

New references in 2019

Ridgeline Therapeutics is the first new reference of 2019. This collaboration highlights that Biocellvia’s technology is very competitive in North America, as Business France published it in 2018. Olivier Julé, Biocellvia’s CEO, took part to a business trip in San Diego in November 2018 to meet potential clients interested in our technology. We can already announce that one of these meetings enabled to changing a lead into a client. Biocellvia has begun a strong collaboration with a major californian biotech.

Last year, we could tell publicly that we had a collaboration with GSK. This “big pharma” is only one of our main references, and most of them prefer remaining confidential. 2019 will be surely a new step for Biocellvia with new references and strong partnerships. Our technology is more and more used by pharmaceutical industry. Biocellvia keeps on developping its market-driven technology. We keep on listening to potential collaborations, business and scientific opportunities.

I have a background as a researcher academic with more than 30 years of age experience. Professor at the "Mayo Clinic " (USA), I created the company Biocellvia in 2011 with my son Olivier Julé. During the creation of the box, I perceived the power of digital image analysis in the framework of the research, and the interest that they cause.

Laisser un commentaire

Votre adresse de messagerie ne sera pas publiée. Les champs obligatoires sont indiqués avec *

We are working hard on our new website!
Unfortunately, we haven't yet found a technology as fast as Biocellvia's .
Please be kind to our old design and come say hello to the new one when it is up and running.